As number of COVID-19 cases in Russia crossed 500,000, the government has rolled out a drug to treat the novel coronavirus even though clinical trials are still underway.
The country's health ministry has approved the use of the anti-viral drug, registered under the name Avifavir, under a special accelerated process.
In a press release, the state financial backer said the drug has been delivered to some hospitals and clinics in the country.
The country's RDIF sovereign wealth fund has a 50 per cent share in a joint venture with the drug's manufacturer ChemRar.
There is currently no vaccine for COVID-19, with human trials of several existing antiviral drugs yet to show efficacy.
So far, the country has 502,436 positive cases and the death toll stands at 6,532.


US House rejects war powers resolution, backs Trump on Iran war
GCC and EU ministers urge immediate halt to Iranian attacks
Trump wants say on Iran's next leader
British PM Starmer to send four Typhoon jets to Qatar
Bombing of Tehran intensifies as war enters day six
Azerbaijan vows to respond after four injured by Iranian drones
72 killed in Israeli attacks on Lebanon as it warns residents to leave south
Nepal goes to the polls; voters seek change after youth-led protests
